From the free articles on MF
Edward Vesely: ResMed Inc. (CHESS) (ASX: RMD)
ResMed recently reported its financial results for the quarter ending 30 September 2016 showing revenue had increased by 13 percent. Margins were also up on the prior corresponding period, despite a fall in net income of 8.2%.
Looking forward, the company’s recent Brightree acquisition puts ResMed in a good place with double-digit earnings growth expected from its new investment in the years ahead. ResMed’s shares have fallen almost 16% from recent highs in early August, which makes this a good time to start or add to your position.
ResMed's profit down despite revenue rise, page-12
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.28 |
Change
0.200(0.54%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.50 | $37.55 | $37.15 | $17.93M | 480.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3363 | $37.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.30 | 1001 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
